Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

France tightens acitretin prescribing rules over pregnancy concerns

This article was originally published in Scrip

Executive Summary

The French regulatory agency ANSM is taking further steps to tighten up on the use of the retinoid acitretin for psoriasis and other skin conditions, after a study showed that women were regularly being prescribed the highly teratogenic drug without having a pregnancy test, and that 357 pregnancies were reported in women taking the product.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC024616

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel